$102.34
-1.90 (-1.82%)
BGSI News30 articles
BitMine Stock Climbs 9% Despite Ether Dominance in Asset Mix
BitMine (NYSE:BMNR) shares rose 9% this week, but its $4B buyback program is overshadowed by massive Ethereum holdings. Ether price swings dwarf repurchase impact.
NuScale Power Gains Despite Revenue Collapse as Cash Position Strengthens
NuScale Power shares climbed 3.7% to $9.82 despite a 99.1% revenue drop, as investors focused on a $1.89B cash position and ongoing strategic progress.
Hertz Stock Soars 29% on Q2 Beat, But Q3 Is the Real Test
Hertz (HTZ) surged 29.5% after beating Q2 earnings estimates, but the full-year forecast depends on Q3. Short covering and strong pricing drove the rally.
Dow Drops 370 Points as Five Stocks Drive Most of the Decline
The Dow Jones Industrial Average fell 370 points, with five stocks accounting for 59% of the decline. Broader markets showed resilience, suggesting sector rotation.
Ford Stock Rises Despite July Sales Drop as Truck Mix Strengthens
Ford (F) shares rose 1.1% despite a 10.2% July sales drop, as trucks gained share and the company raised its 2026 outlook. Truck mix hit 63%.
SoFi's Rebound Puts the Spotlight on Its Ambitious H2 Margin Target
SoFi Technologies (NASDAQ:SOFI) has fully recovered its post-earnings losses, but the stock's rally hinges on the company's ability to deliver a sharp margin expansion in the second half of 2026.
Uber's Cash Conversion Under the Microscope Ahead of Q2 Results
Uber (UBER) reports Q2 earnings amid concerns that booking growth isn't translating into cash, as it prepares a $14.8B Delivery Hero acquisition.
TG Therapeutics Stock Drops 9.8% Despite Strong BRIUMVI Sales as Costs Surge
TG Therapeutics shares fell 9.8% as Q2 revenue rose 70% but operating income declined 38% on surging costs. Guidance raised modestly.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
BitMine Stock Gains 9% Weekly Despite Ether Flat; NAV Discount Narrows
BMNR climbed 9.4% for the week despite a 2.8% drop in Ether. NAV stands at $18.12-$18.48, with shares trading at a discount.
Netflix Slips After $500M Licensing Deal for The Walking Dead Franchise
Netflix shares slipped 0.6% after announcing a $500 million, five-year licensing deal for The Walking Dead franchise, raising questions about the impact on its ad-supported model and overall content spending.
Dow Gains 300 Points, But Microsoft Alone Drives the Rally
The Dow Jones rose 304 points on July 30, 2026, but Microsoft alone accounted for 356 points of the gain, masking weakness in other sectors.
Qantas Project Sunrise Test Flight Success Puts Premium Pricing Strategy to the Test
Qantas cleared a key endurance test for Project Sunrise, but the commercial viability depends on selling 98 premium seats at premium prices.
Microsoft Azure Growth Surprises to the Upside, Easing AI Spending Fears
Microsoft shares gained about 3% in extended trading after Azure revenue surged 43%, surpassing consensus estimates and alleviating market worries about the company's massive AI infrastructure spending.
Oil Spike and Fed Jitters Drag Dow 852 Points; Two Stocks Account for Most of the Drop
US stocks slid midday Wednesday, with the Dow down 852 points, as oil prices surged and the Fed decision approached. Two high-priced components accounted for most of the drop.
Spider-Man Sequel's Record Projection Sparks Theater Stock Rally
Spider-Man: Brand New Day's projected $195M-$250M U.S.-Canada opening could boost theater stocks. Cinemark reports earnings Thursday; Sony releases the film Friday.
From Dive Sites to Air Force One: The Vast Price Gap in Retired 747s
Retired 747s range from a $100,000 reef-destined jet to a $200 million U.S. support aircraft. Boeing (BA) shares edged up 1.2% as services margins outpaced defense. Earnings due Tuesday.
Capricor Therapeutics Plunges 67% on FDA Concerns Over Deramiocel Efficacy
Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.
BitMine Shares Jump 13% on Buyback That Boosts Ether Per Share
BitMine (BMNR) shares climbed 12.8% to $17.81 after the company's buyback program drove a 1.2% increase in ether per share, with repurchases accounting for 86% of the gain.
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
Bitmine's Discount to Asset Value Narrows Sharply Amid Ether Slide
Bitmine Immersion's gross asset discount narrowed to 5-6% from 18% last week, driven almost entirely by Ether's price decline, bringing shares closer to asset value.
Outlook Therapeutics Halts After Lytenava Approval; Cash Concerns Loom
Outlook Therapeutics (OTLK) shares were suspended after FDA approval of Lytenava for wet AMD. The stock rose 23.5% to $1.63, but funding from warrants and cash burn remain key issues.
Bitmine Stock Slips Despite Buyback Driving Ether-Per-Share Growth
Bitmine (NYSE:BMNR) dropped 6.5% to $16.59, with a $85.9M buyback contributing 88% of the weekly Ether-per-share gain.
Dow Plunges 507 Points; Tech Giants Alphabet, Amazon, Salesforce Fuel Nearly Half the Drop
The Dow Jones fell 507 points as Alphabet, Amazon, and Salesforce accounted for nearly half the drop. Oil above $100 and rising rate hike odds added pressure, while Honeywell gained.
Thermo Fisher Stock Surges on Strong Instrument Profit Growth
Thermo Fisher shares rose roughly 10% after Q2 revenue beat estimates and the company boosted its profit outlook, driven by strong margin expansion in Analytical Instruments.
Gerdau Shares Gain as Hydropower Deal Strengthens Energy Cost Hedge
Gerdau's ADR climbed 2.7% to $4.77 after the company acquired a 23.03% stake in hydro generator DFESA for R$154 million, advancing its energy hedging strategy.
Rani Therapeutics Soars 29%, Narrows Nasdaq Compliance Gap to 11%
Rani Therapeutics shares jumped 29.4% to $0.89, reducing the gap to Nasdaq's $1 minimum bid to about 11%. CEO Talat Imran's open-market purchase and promising Phase 1a results for RT-114 fueled the rally.
Bitmine Buyback Boosts Ether Per Share, Driving Weekly Gains
Bitmine's latest share buyback drove a 1.05% Ether-per-share gain, with 88% from reduced share count. Stock rose 4.6% to $18.02.
Ethereum's Price Rally Masks Decline in Tokenized Real-World Asset Dominance
Ethereum's price rose 8.3% in the past week, but its tokenized real-world asset value fell 8.2% over 30 days, while Solana and Stellar saw increases.
Bitmine Stock Buyback Boosts ETH Per Share More Than Direct Ether Purchase
Bitmine's $85.9M share buyback lifted ETH per share by 0.92%, surpassing the 0.79% gain from a direct Ether purchase, signaling accretive capital management.